Comparison of clinical characteristics and survival after surgery in patients with non-B and non-C hepatocellular carcinoma and hepatitis virus-related hepatocellular carcinoma

Journal of Cancer

Volumn 4, Issue 6, 2013, Pages 502-513

  Nishikawa, Hiroki ^a   Arimoto, Akira ^a   Wakasa, Tomoko ^a   Kita, Ryuichi ^a   Kimura, Toru ^a   Osaki, Yukio ^a  

^a OSAKA RED CROSS HOSPITAL   (Japan)

Author keywords

Non B and non C hepatocellular carcinoma; overall survival; prognostic factor.; recurrence free survival; surgery

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; DECARBOXYPROTHROMBIN; GAMMA GLUTAMYLTRANSFERASE; SERUM ALBUMIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CANCER MORTALITY; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CLINICAL ASSESSMENT TOOL; DIABETES MELLITUS; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MILAN CRITERIA; OVERALL SURVIVAL; PROTHROMBIN TIME; RECURRENCE FREE SURVIVAL; THROMBOCYTE COUNT; TREATMENT OUTCOME; TUMOR DIFFERENTIATION;

EID: 84883017148     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.6503     Document Type: Article

References (31)

1. Kudo M. Radiofrequency ablation for hepatocellular carcinoma: updated review in 2010. Oncology. 2010; 78: 113-124.
2. Livraghi T, Mäkisalo H, Line PD. Treatment options in hepatocellular carcinoma today. Scand J Surg. 2011; 100: 22-29.
3. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012; 142: 1264-73.
4. Nishikawa H, Osaki Y, Iguchi E, et al. Radiofrequency ablation for hepatocellular carcinoma: the relationship between a new grading system for the ablative margin and clinical outcomes. J Gastroenterol. 2012; [Epub ahead of print]
5. Zhou WP, Lai EC, Li AJ, et al. A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Ann Surgery. 2009; 249: 195-202.
6. Nishikawa H, Osaki Y, Kita R, et al. Transcatheter arterial infusion chemotherapy prior to radiofrequency thermal ablation for single hepatocellular carcinoma reduces the risk of intrahepatic distant recurrence. Int J Oncol. 2012; 41: 903-9.
7. Takuma Y, Nouso K, Makino Y, et al. Outcomes after curative treatment for cryptogenic cirrhosis-associated hepatocellular carcinoma satisfying the Milan criteria. J Gastroenterol Hepatol. 2011; 26(9): 1417-24.
8. Kaibori M, Ishizaki M, Matsui K, Kwon AH. Clinicopathologic characteristics of patients with non-B non-C hepatitis virus hepatocellular carcinoma after hepatectomy. Am J Surg. 2012; 204(3): 300-7.
9. Akahoshi H, Taura N, Ichikawa T, et al. Differences in prognostic factors according to viral status in patients with hepatocellular carcinoma. Oncol Rep. 2010; 23(5): 1317-23
10. Utsunomiya T, Shimada M. Molecular characteristics of non-cancerous liver tissue in non-B non-C hepatocellular carcinoma. Hepatol Res. 2011; 41: 711-721.
11. Umemura T, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. Hepatol Res. 2007; 37 Suppl 2: S95-S100.
12. Hatanaka K, Kudo M, Fukunaga T, et al. Clinical characteristics of NonBNonC-HCC: Comparison with HBV and HCV related HCC. Intervirology. 2007; 50(1): 24-31.
13. Yang JD, Harmsen WS, Slettedahl SW, et al. Factors that affect risk for hepatocellular carcinoma and effects of surveillance. Clin Gastroenterol Hepatol. 2011; 9(7): 617-23.
14. Bruix J and Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma. Hepatology. 2005; 42: 1208-1236.
15. Liver Cancer Study Group of Japan: The general rules for the clinical and pathological study of primary liver cancer. Jpn J Surg 1989; 19: 98-129.
16. Li T, Qin LX, Gong X, et al. Hepatitis B virus surface antigen-negative and hepatitis C virus antibody-negative hepatocellular carcinoma: clinical characteristics, outcome, and risk factors for early and late intrahepatic recurrence after resection. Cancer. 2013; 119(1): 126-35.
17. Paradis V, Zalinski S, Chelbi E, et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology. 2009; 49(3): 851-9.
18. Reddy SK, Steel JL, Chen HW, et al. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology. 2012; 55(6): 1809-19.
19. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology. 2010; 51(5): 1820-32.
20. McGivern DR, Lemon SM. Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer. Oncogene. 2011; 30(17): 1969-83.
21. Farinati F, Cardin R, Bortolami M, et al. Hepatitis C virus: from oxygen free radicals to hepatocellular carcinoma. J Viral Hepat. 2007; 14(12): 821-9.
22. Fung J, Lai CL, Yuen MF. Hepatitis B and C virus-related carcinogenesis. Clin Microbiol Infect. 2009; 15(11): 964-70.
23. [No authors listed] Long-term oral administration of branched chain amino acids after curative resection of hepatocellular carcinoma: a prospective randomized trial. The San-in Group of Liver Surgery. Br J Surg. 1997; 84(11): 1525-31.
24. Nishikawa H, Osaki Y, Iguchi E, et al. The Effect of Long-term Supplementation With Branched-chain Amino Acid Granules in Patients With Hepatitis C Virus-related Hepatocellular Carcinoma After Radiofrequency Thermal Ablation. J Clin Gastroenterol. 2013; 47(4): 359-66.
25. Haruhiko Takeda, Hiroki Nishikawa, Eriko Iguchi, et al. Effect of branched-chain amino acid treatment during sorafenib therapy for unresectable hepatocellular carcinoma. Hepatol Research 2013; in press.
26. WHO. Obesity-preventing and managing the global epidemic Report of WHO consultation on obesity. Geneva: WHO. 1997.
27. Yao D, Jiang D, Huang Z, et al. Abnormal expression of hepatoma specific gamma-glutamyl transferase and alteration of gamma-glutamyl transferase gene methylation status in patients with hepatocellular carcinoma. Cancer. 2000; 88(4): 761-9.
28. Zhang JB, Chen Y, Zhang B, et al. Prognostic significance of serum gamma-glutamyl transferase in patients with intermediate hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Eur J Gastroenterol Hepatol. 2011; 23(9): 787-93.
29. Ju MJ, Qiu SJ, Fan J, et al. Preoperative serum gamma-glutamyl transferase to alanine aminotransferase ratio is a convenient prognostic marker for Child-Pugh A hepatocellular carcinoma after operation. J Gastroenterol. 2009; 44(6): 635-42.
30. Nakashima T, Kojiro M. Pathologic characteristics of hepatocellular carcinoma. Semin Liver Dis. 1986; 6(3): 259-66.
31. Lim KC, Chow PK, Allen JC, et al: Microvascular invasion is a better predictor of tumor recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria. Ann Surg. 2011; 254: 108-113.